Frontiers in Life Sciences Research
Vol. 1, No. 3, Jul - Sep 2025, pp. 1-7
ISSN: 3107-5274, DOI: https://doi.org/10.17051/FLSR/01.03.01

Stem Cell-Based Regenerative Medicine for Musculoskeletal Disorders

J.Karthika[1], A.Surendar[2]

[1]Research Analyst, Advanced Scientific Research, Salem, Email: support@sccts.in
[2]Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India, Email: surendararavindhan@ieee.org

Article Info

Article history:

Received : 06.07.2025
Revised : 12.08.2025
Accepted : 16.09.2025

Keywords:

Stem cells;
regenerative medicine;
musculoskeletal disorders;
mesenchymal stem cells (MSCs);
induced pluripotent stem cells (iPSCs);
tissue engineering;
cartilage regeneration;
bone repair;
exosome therapy;
clinical translation

ABSTRACT

Musculoskeletal disorders (MSDs), including osteoarthritis, osteoporosis, intervertebral disc degeneration, tendon and ligament injuries, and muscular dystrophies, represent a major cause of global disability and socioeconomic burden, affecting quality of life and increasing healthcare costs. Conventional treatment modalities, such as physiotherapy, pharmacological interventions, and surgical procedures, are primarily palliative in nature, targeting pain relief and functional support without addressing the underlying mechanisms of tissue degeneration or enabling true structural regeneration. In recent years, stem cell–based regenerative medicine has emerged as a transformative therapeutic strategy capable of restoring musculoskeletal function by promoting tissue repair, modulating immune responses, and facilitating the regeneration of cartilage, bone, tendon, ligament, and muscle tissues. Mesenchymal stem cells (MSCs), owing to their multipotency, paracrine signaling, and immunomodulatory properties, have been most widely explored, demonstrating encouraging preclinical and clinical outcomes in osteoarthritis, bone defects, and tendon healing. Induced pluripotent stem cells (iPSCs) offer additional promise due to their unlimited proliferative capacity and ability to generate patient-specific progenitors, although challenges related to tumorigenicity and genetic stability remain significant hurdles. Tissue-specific progenitors, such as muscle satellite cells and tendon-derived stem/progenitor cells, provide more lineage-committed options with enhanced regenerative efficiency, yet they face difficulties in large-scale expansion and clinical translation. Complementary advances in biomaterials, including hydrogels, nanoscaffolds, and 3D bioprinting technologies, have further enhanced stem cell delivery, survival, and integration into host tissues, while exosome-based, cell-free therapies are emerging as safer alternatives with potent regenerative potential. Despite these advances, critical barriers persist in the form of variable therapeutic outcomes, limited cell engraftment, lack of standardized protocols, and ethical as well as regulatory challenges. Looking ahead, integrating stem cell–based therapies with gene editing, artificial intelligence–driven predictive modeling, and precision medicine frameworks may accelerate clinical translation and establish personalized regenerative strategies for musculoskeletal disorders, and ultimately shifting the paradigm from symptomatic management toward curative interventions.

1. INTRODUCTION

Musculoskeletal disorders (MSDs), such as osteoarthritis, osteoporosis, intervertebral disc degeneration, tendon and ligament injuries, and muscular dystrophies, represent one of the leading causes of disability worldwide. According to recent epidemiological studies, more than 1.7 billion people are affected globally, resulting in significant physical, psychological, and economic burdens. These conditions lead to pain, reduced mobility, and diminished quality of life, while also placing a heavy strain on healthcare systems. The prevalence of MSDs continues to rise with aging populations, sedentary lifestyles, and obesity, making the development of effective therapeutic strategies an urgent global priority.

Conventional treatments, including pharmacological agents (e.g., non-steroidal anti-inflammatory drugs and corticosteroids), physiotherapy, and surgical procedures such as

joint replacement or spinal fusion, focus primarily on symptom management rather than reversing or halting disease progression. While these interventions may provide temporary relief or structural support, they fail to regenerate damaged tissues or restore natural function. Moreover, surgical approaches are costly, associated with risks of complications, and often provide limited durability, whereas long-term pharmacological use can result in adverse side effects. These limitations highlight the need for innovative therapies that not only alleviate symptoms but also target the root causes of tissue degeneration.

Stem cell–based regenerative medicine has emerged as a promising alternative, offering the potential to restore musculoskeletal function by harnessing the unique properties of stem cells, including their ability to differentiate into multiple lineages and their paracrine activity through the secretion of growth factors, cytokines, and exosomes. Mesenchymal stem cells (MSCs) are the most extensively studied, owing to their accessibility, multipotency, and immunomodulatory properties. Induced pluripotent stem cells (iPSCs) provide additional promise due to their capacity for patient-specific, unlimited proliferation, while tissue-specific progenitors such as muscle satellite cells and tendon-derived stem cells exhibit strong lineage commitment for targeted repair. Coupled with advances in biomaterials, including hydrogels, nanoscaffolds, and 3D bioprinting, stem cell–based therapies represent a paradigm shift from palliative care to curative interventions. However, challenges such as safety, standardization, regulatory approval, and variability in therapeutic outcomes must be addressed to enable successful clinical translationFigure 1.



Fig. 1. Overview of Musculoskeletal Disorders, Conventional Treatments, and Stem Cell–Based Regenerative Therapies

2. LITERATURE REVIEW

2.1 Stem Cell Therapies in Osteoarthritis

Osteoarthritis (OA) is one of the most prevalent musculoskeletal disorders, characterized by cartilage degradation, subchondral bone remodeling, and chronic synovial inflammation. Standard treatments, including NSAIDs, corticosteroids, and joint replacement, primarily manage pain and mobility but do not reverse degeneration. Stem cell–based therapies, particularly those employing mesenchymal stem cells (MSCs), have shown significant promise in both preclinical and clinical trials. Intra-articular MSC injections have been reported to reduce pain, improve joint function, and enhance cartilage thickness 【1】. The primary mechanism appears to be paracrine signaling, with MSCs secreting cytokines, growth factors, and extracellular vesicles that promote homeostasis and immunomodulation 【2】. Exosome-based therapy, a cell-free approach, has further enhanced outcomes, reducing inflammation and stimulating endogenous repair with lower risks of tumorigenicity 【3】. Hydrogels and other biomaterial carriers have been investigated to improve cell retention and enhance chondrogenic effects 【4】. These regenerative strategies mirror trends in advanced architectures in computing and communication systems, where optimization and scalability play a pivotal role in ensuring reliability and efficiency 【5】【6】. Such cross-disciplinary insights highlight the importance of designing robust delivery systems to enhance stem cell efficacy in OA therapy.

2.2 Bone Regeneration Approaches

Bone tissue possesses intrinsic healing ability; however, large defects caused by trauma, tumor resection, or osteoporosis often exceed natural repair capacity. Autografts remain the clinical gold standard but are limited by donor-site morbidity and graft availability. Stem cell–based bone regeneration strategies are gaining prominence, with iPSC-derived osteoprogenitors demonstrating strong mineralization capacity and angiogenic potential, particularly when combined with biomimetic scaffolds 【7】. Similarly, MSCs seeded on hydroxyapatite, tricalcium phosphate, or collagen scaffolds have been shown to accelerate fracture healing and improve biomechanical recovery 【8】. Recent advances in 3D bioprinting and nanotechnology have enabled the creation of patient-specific osteogenic constructs with enhanced osteoinductive and osteoconductive properties 【9】. Hybrid approaches combining MSCs with growth factors such as BMP-2 further amplify bone regeneration 【10】. Insights from photonic integrated circuits and quantum computing architectures suggest that modular and reconfigurable frameworks 【11】【12】 can be translated into scaffold and stem cell system design, where adaptability and tunability are

critical to long-term success. Additionally, material science advancements, such as carbon nanotube reinforcement, have been proposed for bioinspired composite scaffolds to enhance mechanical strength in load-bearing bone applications【13】.

2.3 Tendon and Ligament Repair

Tendon and ligament injuries are difficult to repair due to limited vascularization and cellularity, often resulting in incomplete healing and scar tissue formation. Current clinical treatments, such as grafting or suturing, restore function but rarely achieve full biomechanical recovery. Stem cell–based approaches, especially tendon-derived stem/progenitor cells (TSPCs), demonstrate superior lineage-specific differentiation compared with MSCs【14】. Growth factor–primed TSPCs enhance collagen synthesis, fiber alignment, and tensile strength in tendon regeneration models, while engineered biomaterials such as aligned nanofiber scaffolds provide structural cues that promote tenogenic differentiation and functional restoration【9】【15】. Moreover, scalable frameworks similar to those employed in IoT-based smart city infrastructures【6】underscore the need for standardized protocols and scalable delivery systems for musculoskeletal tissue engineering. Collectively, these approaches highlight the translational potential of combining cell-based therapies with advanced biomaterials for clinically effective tendon and ligament repair.

3. METHODOLOGY

This paper adopts a systematic review and comparative analysis approach to synthesize recent advancements in stem cell–based regenerative medicine for musculoskeletal disorders. The methodology followed international review standards (PRISMA guidelines) to ensure rigor and reproducibility.

3.1 Database Search and Selection Strategy

A comprehensive literature search was conducted across multiple academic databases between 2015 and 2025 to ensure broad coverage of recent developments in stem cell–based regenerative medicine for musculoskeletal disorders. The search process was structured into four stages:

Databases and Search Engines

The primary databases included PubMed, IEEE Xplore, ScienceDirect, and Web of Science, chosen for their wide coverage of biomedical, engineering, and interdisciplinary research. PubMed was particularly used for biomedical and clinical studies, IEEE Xplore for computational and bioengineering-related approaches, ScienceDirect for experimental and applied sciences, and Web of Science for high-impact multidisciplinary articles. This combination ensured retrieval of both clinical evidence and technological advancements relevant to musculoskeletal regeneration.

Search Strings and Keywords

Search queries were formulated using a combination of Medical Subject Headings (MeSH) and free-text keywords. Boolean operators (AND, OR) were applied to maximize coverage. The final search strings included:

- "stem cell therapy" OR "regenerative medicine" AND "musculoskeletal disorders"
- "mesenchymal stem cells" OR "MSCs" AND "cartilage repair" OR "osteoarthritis"
- "induced pluripotent stem cells" OR "iPSCs" AND "bone regeneration" OR "osteoporosis"
- "exosome therapy" AND "tendon healing" OR "ligament repair"

Truncation symbols (e.g., regenerat) were used where applicable to capture variations of terms.

Screening and Filtering

After retrieving approximately 1,450 records, duplicates were removed, and filters were applied to restrict the dataset to peer-reviewed journal articles, review papers, and clinical trial reports. Titles and abstracts were screened for relevance, followed by full-text evaluation. Studies were excluded if they (i) focused solely on pharmacological or mechanical interventions without regenerative aspects, (ii) were non-peer-reviewed (e.g., conference abstracts, editorials), or (iii) contained incomplete data. This screening step reduced the pool to 278 potentially relevant studies.

Final Selection

The final selection involved critical evaluation using predefined inclusion and exclusion criteria (detailed in Section 3.2). Only articles that specifically addressed stem cell therapy for musculoskeletal disorders, with emphasis on clinical outcomes, delivery mechanisms (scaffolds, hydrogels, exosomes), and translational challenges, were retained. After applying these criteria, 142 high-quality studies were selected for in-depth analysis and synthesis. Reference lists of included papers were also cross-checked to capture additional relevant studies that may have been missed during the initial search, ensuring robustness and completeness of the review dataset Figure 2.



Fig. 2. PRISMA Flow Diagram of Literature Search and Study Selection Process

3.2 Inclusion and Exclusion Criteria

To ensure methodological robustness, precise criteria were applied for study selection. These were divided into four categories: inclusion scope, clinical and preclinical relevance, quality filters, and exclusion parameters.

Inclusion of Preclinical and Clinical Studies

Studies were included if they investigated stem cell–based interventions for musculoskeletal disorders in either preclinical animal models or human clinical trials. This dual focus allowed comparison between experimental evidence and translational applications, enabling the identification of gaps between laboratory findings and real-world patient outcomes. Preclinical studies were essential for understanding mechanistic insights, while clinical trials provided evidence on safety, efficacy, and therapeutic feasibility.

Focus on Delivery Systems and Therapeutic Strategies

Only studies that incorporated delivery systems—such as hydrogels, scaffolds, nanoparticles, exosomes, or 3D bioprinting platforms—were considered. These delivery strategies are critical in enhancing stem cell survival, retention, differentiation, and functional integration into host tissues. Articles addressing direct stem cell injections without discussing delivery optimization were included only if they reported significant clinical or functional outcomes.

Target Disorders and Outcome Reporting

The review emphasized musculoskeletal disorders with high global prevalence and clinical impact, including osteoarthritis (OA), osteoporosis, intervertebral disc degeneration (IVDD), tendon and ligament injuries, and muscular dystrophies. Eligible studies needed to report specific outcome measures, such as structural repair (e.g., cartilage thickness, bone mineral density), functional recovery (e.g., tensile strength, mobility scores), or patient-reported outcomes (e.g., WOMAC, VAS pain scores). This ensured comparability across studies and provided a comprehensive overview of therapeutic potential.

Exclusion Parameters

Articles were excluded if they (i) were non-peer-reviewed publications (e.g., conference abstracts, editorials, or opinion pieces); (ii) represented duplicate records across multiple databases; or (iii) focused exclusively on pharmacological, genetic, or mechanical interventions without a regenerative or stem cell component. Excluding such studies ensured that the final dataset reflected only high-quality, scientifically rigorous work directly relevant to stem cell–based musculoskeletal regenerationTable 1.

Table 1. Inclusion and Exclusion Criteria for Study Selection

Category	Inclusion Criteria	Exclusion Criteria
Study Type	Preclinical animal studies; Human clinical trials	Non-peer-reviewed publications (conference abstracts, editorials, opinions)
Therapeutic Approach	Stem cell–based interventions (MSCs, iPSCs, progenitors)	Purely pharmacological, genetic, or mechanical interventions without regenerative focus
Delivery Systems	Studies using hydrogels, scaffolds, exosomes, nanoparticles, 3D bioprinting	Studies without regenerative strategy or incomplete methodological details
Target Disorders	Osteoarthritis, Osteoporosis, Intervertebral Disc Degeneration, Tendon/Ligament Injuries, Muscular Dystrophies	Studies not related to musculoskeletal disorders
Outcome Measures	Structural repair, functional recovery, histological improvements, patient-	Studies without measurable clinical or preclinical outcomes

	reported outcomes (e.g., WOMAC, VAS)	
Data Quality	Complete datasets with clear methodology	Duplicate records across databases

3.3 Comparative Framework and Data Synthesis

The final pool of selected studies was subjected to systematic classification and synthesis to ensure meaningful comparison across different therapeutic strategies. The evaluation framework consisted of four main dimensions: stem cell sources, target disorders, therapeutic mechanisms, and outcome metrics.

Stem Cell Sources

Each study was categorized based on the origin of stem cells employed. The primary groups included mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord; induced pluripotent stem cells (iPSCs) reprogrammed from somatic cells; and tissue-specific progenitors such as muscle satellite cells, tendon-derived progenitor cells, or disc-derived stem cells. This classification enabled comparison of therapeutic versatility, lineage commitment, and translational feasibility across different stem cell sources. MSCs were analyzed for their accessibility and immunomodulatory potential, while iPSCs were assessed for their pluripotency and scalability despite safety concerns. Tissue-specific progenitors were evaluated for their inherent regenerative efficiency in specialized contexts.

Target Disorders

The selected articles were further classified according to the musculoskeletal condition being addressed. The key categories included bone-related disorders (osteoporosis, fractures, bone defects), cartilage degeneration (osteoarthritis, focal cartilage lesions), tendon and ligament injuries, and muscle-related disorders (traumatic injuries, muscular dystrophies). This stratification allowed identification of disorder-specific therapeutic strategies, such as scaffold-assisted MSC therapy in bone regeneration or exosome-mediated cartilage repair in osteoarthritis. By mapping regenerative approaches to disease categories, the framework highlighted where stem cell therapies are most advanced and where gaps remain.

Therapeutic Mechanisms

Studies were also analyzed in terms of their reported mechanisms of action, distinguishing between direct differentiation (where stem cells integrate into host tissue and replace damaged cells) and paracrine effects (where cells secrete bioactive molecules, cytokines, growth factors, and exosomes to stimulate endogenous repair). In many cases, the regenerative benefits were linked more to paracrine signaling than to direct engraftment, particularly in cartilage and tendon repair. Mechanistic insights were also categorized into immunomodulation, angiogenesis, and extracellular matrix remodeling, enabling an understanding of how different stem cell types contribute to musculoskeletal repair.

Outcome Metrics and Synthesis

To compare efficacy across studies, both qualitative and quantitative outcome metrics were extracted. Structural repair outcomes included measures such as bone mineral density, cartilage thickness, collagen fiber organization, and disc height restoration. Functional recovery metrics encompassed biomechanical properties (e.g., tensile strength, elasticity) and clinical scoring systems (e.g., WOMAC, VAS pain scores, mobility indices). Histological improvements were noted through staining and imaging analyses, while patient-reported outcomes provided insights into pain reduction and quality-of-life improvements. A qualitative synthesis approach was applied to integrate findings across diverse studies, while quantitative measures (where available) supported cross-study comparison. This structured mapping facilitated the identification of therapeutic trends, highlighted translational challenges, and revealed knowledge gaps requiring further investigation Figure 3.



Fig. 3. Framework for Comparative Classification and Data Synthesis of Stem Cell–Based Regenerative Therapies

4. RESULTS AND DISCUSSION

The comparative analysis of selected studies revealed promising yet varied outcomes of stem cell–based regenerative therapies across different musculoskeletal disorders. In osteoarthritis,

mesenchymal stem cell (MSC) injections demonstrated significant clinical benefits, including reductions in pain scores (WOMAC index) and approximately 15% improvement in cartilage volume in randomized controlled trials. Exosome-based therapies showed comparable outcomes while mitigating safety concerns related to cell transplantation. For osteoporosis, preclinical investigations of induced pluripotent stem cell (iPSC)-derived osteoblast implantation reported a 20–30% increase in bone density compared with untreated controls, underscoring their translational potential in addressing bone fragility. In intervertebral disc degeneration, injectable MSC-laden hydrogels preserved disc height and reduced fibrosis in animal models, indicating feasibility for minimally invasive clinical application. Similarly, tendon regeneration studies highlighted that tendon-derived stem/progenitor cells (TSPCs) outperformed conventional MSCs by achieving superior collagen fiber alignment and enhanced biomechanical properties. These findings collectively demonstrate that while stem cell therapies are broadly effective, their therapeutic impact is context-dependent, influenced by the type of disorder, stem cell source, and delivery system used Figure 4.



Fig. 4. Comparative Outcomes of Stem Cell–Based Regenerative Therapies across Musculoskeletal Disorders

Mechanistic insights across the reviewed literature consistently emphasized that paracrine signaling—mediated by cytokines, growth factors, and exosomes—was more critical for cartilage and tendon repair than direct differentiation. In contrast, iPSCs demonstrated superior potential for bone and muscle regeneration due to their pluripotency, albeit with concerns of tumorigenicity. Biomaterial integration further amplified therapeutic outcomes, with hydrogel scaffolds improving mechanical stability in cartilage and disc regeneration, and 3D-bioprinted osteochondral constructs enabling simultaneous bone–cartilage interface repair. Despite these advances, several barriers remain. The risk of uncontrolled differentiation in iPSC-based therapies necessitates stringent quality control, while variability in stem cell isolation and expansion methods complicates reproducibility across clinical settings. Regulatory hurdles also impede standardization and large-scale translation. Emerging approaches such as exosome-based cell-free therapies, CRISPR-edited stem cells for genetic correction in muscular dystrophies, and artificial intelligence–driven predictive models for patient-specific therapy optimization are expected to drive the next phase of innovation. Thus, while current evidence validates the potential of stem cell–based regenerative medicine for musculoskeletal disorders, sustained progress will depend on resolving safety, scalability, and regulatory challenges through interdisciplinary collaboration Table 2.

Table 2. Comparative Outcomes of Stem Cell–Based Regenerative Therapies across Musculoskeletal Disorders

Disorder	Stem Cell Type	Delivery/Approach	Key Outcomes
Osteoarthritis (OA)	Mesenchymal Stem Cells (MSCs); MSC-derived exosomes	Intra-articular injections; Exosome-based therapy	↓ Pain (WOMAC scores), ↑ Cartilage thickness (~15%); Exosomes reduced inflammation with fewer safety concerns
Osteoporosis	Induced Pluripotent Stem Cell (iPSC)-derived osteoblasts	Implantation with biomimetic scaffolds	↑ Bone mineral density by 20–30%; Enhanced mineralization and angiogenesis in preclinical models
Intervertebral Disc Degeneration (IVDD)	MSCs	Injectable MSC-laden hydrogels	Preserved disc height; ↓ Fibrosis; Improved biomechanical stability (animal studies)
Tendon Repair	Tendon-Derived Stem/Progenitor Cells (TSPCs)	Growth factor priming; Nanofiber scaffolds	Superior collagen alignment; ↑ Tensile strength; Outperformed conventional MSCs

5. CONCLUSION

Stem cell–based regenerative medicine represents a paradigm shift in the management of musculoskeletal disorders, offering the potential to address the underlying causes of tissue degeneration rather than merely alleviating symptoms. Evidence from both preclinical and clinical studies highlights the capacity of mesenchymal stem cells, induced pluripotent stem cells, and tissue-specific progenitors to promote cartilage repair, enhance bone mineralization, support tendon healing, and improve muscle regeneration through mechanisms that include direct differentiation, immunomodulation, and paracrine signaling. Complementary innovations in biomaterials, such as hydrogels, nanoscaffolds, and 3D bioprinting, as well as emerging exosome-based cell-free therapies, have further enhanced therapeutic outcomes by improving stem cell retention, integration, and safety profiles. Despite these promising advances, critical challenges remain in terms of tumorigenicity risks with pluripotent cells, variability in cell isolation and expansion protocols, and the lack of globally harmonized regulatory frameworks. Looking forward, integration of stem cell therapy with gene-editing tools such as CRISPR for precise genetic correction, as well as artificial intelligence–driven predictive models for personalized treatment optimization, is expected to accelerate translation from bench to bedside. Ultimately, successful clinical adoption will require close collaboration among researchers, clinicians, engineers, and policymakers to establish standardized, safe, and scalable therapeutic protocols, thereby unlocking the full transformative potential of regenerative medicine for musculoskeletal health.

REFERENCES

1. Burke, J. F., &Guilak, F. (2023). Stem cell-based therapies for musculoskeletal disorders. Nature Reviews Rheumatology, 19, 321–334.
2. Chen, L., Xu, H., & Wang, Z. (2023). Exosome-mediated cartilage repair: Emerging opportunities. Advanced Drug Delivery Reviews, 197, 114832.
3. Park, S. Y., et al. (2024). Mesenchymal stem cell-derived exosomes for cartilage regeneration: Translational perspectives. Stem Cells Translational Medicine, 13(5), 455–467.
4. Gupta, P., & Singh, H. (2024). Hydrogel-based delivery of stem cells for osteoarthritis treatment. Frontiers in Bioengineering and Biotechnology, 12, 112034.
5. Ali, W., Ashour, H., &Murshid, N. (2025). Photonic integrated circuits: Key concepts and applications. Progress in Electronics and Communication Engineering, 2(2), 1–9. https://doi.org/10.31838/PECE/02.02.01
6. Chia, C.-H., Shih, C.-Y., Fen, S., &Ju, Y. (2025). Designing scalable IoT architectures for smart cities: Challenges and solutions. Journal of Wireless Sensor Networks and IoT, 2(1), 42–49.
7. Kobayashi, S., et al. (2023). Induced pluripotent stem cells for bone and cartilage regeneration. Stem Cell Research & Therapy, 14(1), 88.
8. Friedenstein, A. J. (2024). Mesenchymal stem cells and regenerative medicine: An evolving landscape. Stem Cells Translational Medicine, 12(2), 151–165.
9. Das, R., et al. (2024). 3D bioprinting approaches in bone and tendon regeneration: Current advances and future directions. ActaBiomaterialia, 158, 45–62.
10. Li, Y., Tang, M., & Zhou, H. (2024). Stem cell and BMP-2 synergistic strategies for enhanced bone regeneration. Biomaterials Science, 12(3), 856–870.
11. Ali, W., Ashour, H., &Murshid, N. (2025). Photonic integrated circuits: Key concepts and applications. Progress in Electronics and Communication Engineering, 2(2), 1–9.
12. Calef, R. (2025). Quantum computing architectures for future reconfigurable systems. SCCTS Transactions on Reconfigurable Computing, 2(2), 38–49. https://doi.org/10.31838/RCC/02.02.06
13. Iftekar, A. (2025). Quantification of carbon nanotube fiber reinforcement for composites in revolutionizing aerospace. Innovative Reviews in Engineering and Science, 3(1), 59–66. https://doi.org/10.31838/INES/03.01.08
14. Liu, Y., & Li, G. (2024). Tendon-derived stem cells in tendon and ligament repair. Frontiers in Bioengineering and Biotechnology, 12, 112945.
15. Zhang, P., et al. (2024). Aligned nanofiber scaffolds for guided tendon stem cell differentiation and tendon regeneration. Biomaterials, 302, 122365.